<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00590018</url>
  </required_header>
  <id_info>
    <org_study_id>H-12030</org_study_id>
    <nct_id>NCT00590018</nct_id>
  </id_info>
  <brief_title>Corticosteroids in Postoperative Critically Ill Neonates With Low Cardiac Output Syndrome With Congenital Heart Disease</brief_title>
  <acronym>Corti</acronym>
  <official_title>Corticosteroids in Postoperative Critically Ill Neonates With Low Cardiac Output Syndrome With Congenital Heart Disease</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Baylor College of Medicine</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Baylor College of Medicine</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Babies having heart surgery often have problems after surgery with their blood pressure and
      getting enough blood to their bodies. To treat this they require medicines to keep their
      blood pressure high enough to get blood to their bodies. The side effects of these medicines
      include fast heart rates and increasing the amount of work the heart has to do.
      Corticosteroids are made by the body and help to use the energy in the food people eat,
      control the chemicals in their blood and maintain their blood pressure. Corticosteroids made
      by the body may be decreased in patients that have major surgery. Corticosteroids help to
      increase blood pressure and can decrease the amount of blood pressure medicines a patient
      requires. Corticosteroids have been shown to increase blood pressure in patients with
      bacterial infections and in very small, premature babies but have only been studied in a few
      babies who have had heart surgery. The way corticosteroids work is unknown but may involve
      decreasing the body's response to being on a heart-lung machine or give steroids not being
      made by the patient.

      Corticosteroids have been shown to be helpful in treating many diseases. The purpose of this
      study is to look at the effects of corticosteroids in babies who have had heart surgery and
      need blood pressure medicines in the intensive care unit after surgery. Our idea is that
      getting corticosteroids will allow us to decrease the amount of blood pressure medicines each
      patient needs and improve how they do after surgery. We also plan to do blood tests to help
      determine how the corticosteroids are working.

      It will be randomly determined if the subject receives corticosteroids or salt water. The
      subject will receive a corticosteroid or salt water once a day for five days. Their vital
      signs will be monitored, especially blood pressure and their need for medicines to increase
      their blood pressure. Blood work will also be obtained to determine their body's ability to
      make steroids.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The study will be prospective. Patients who meet entry criteria will be randomized to receive
      corticosteroids versus placebo. Randomization will take into account biventricular versus
      univentricular repairs/palliations and whether the patients received intraoperative steroids.
      Patients will be compared with matched controls based on: diagnosis, +/- intraoperative
      steroids/phenoxybenzamine, cardiopulmonary bypass/cross clamp/circulatory arrest times and
      inotrope requirements. Those in the treatment arm will be dosed with hydrocortisone - stress
      dose (100mg/m2/dose daily x2, then taper with two days at half the original dose and one day
      at one quarter of the original dose) and then the steroids will be discontinued. Outcome data
      will include: heart rate, blood pressure, mixed venous oxygen saturation to assess cardiac
      output, blood cultures/infection/antibiotics (antibiotics as deemed necessary by the primary
      cardiologist), +/- gastrointestinal bleeding, time to discontinuing inotropic agents, time to
      extubation, length of intensive care unit admission and survival. Laboratory studies will be
      assessed before and 24 hours after the institution of steroids. The following labs are
      standard of care in the unit and will be assessed: glucose, electrolytes, blood urea
      nitrogen/creatinine, complete blood counts, lactate, arterial blood gases, cultures and stool
      guaiac. The following labs will be assessed in addition to regular monitoring: cortisol,
      adrenocorticotropin hormone and C reactive protein.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>February 2003</start_date>
  <completion_date type="Actual">December 2009</completion_date>
  <primary_completion_date type="Actual">December 2009</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Triple (Participant, Care Provider, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Blood Pressure.</measure>
    <time_frame>2 days</time_frame>
    <description>Change in mean blood pressure recorded prior to (15 minutes prior to study drug) and subsequent to medication/placebo administration (at 2 days post drug administration).</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Change in Inotrope Score. This is the Change in the Inotrope Score Between 15 Minutes Prior to Drug Administration and at 2 Days After Drug Administration.</measure>
    <time_frame>2 days</time_frame>
    <description>Inotrope score: epinephrine (mcg/kg/min x 100) + norepinephrine (mcg/kg/min x 100) + phenylephrine (mcg/kg/min x 100) + dopamine (mcg/kg/min x1) + dobutamine (mcg/kg/min x 1) + milrinone (mcg/kg/min x15). A lower inotrope score is better with the minimum being 0 and the maximum being 85.</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">18</enrollment>
  <condition>Cardiac Output, Low</condition>
  <arm_group>
    <arm_group_label>1</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Subjects in this arm will receive a 5 day tapering course of hydrocortisone.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>2</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Subjects in this arm will receive 5 days of placebo.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Hydrocortisone</intervention_name>
    <description>Hydrocortisone taper (100mg/m2/day --&gt; 25mg/m2/day) over 5 days intravenously.</description>
    <arm_group_label>1</arm_group_label>
    <other_name>Corticosteroids.</other_name>
    <other_name>Steroids.</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Placebo for 5 days intravenously.</description>
    <arm_group_label>2</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Age &lt; 1 month

          -  Postoperative

          -  Inotrope score &gt; 20 x &gt; 4 hrs [epinephrine: (mcg/kg/min) x 100 + norepinephrine:
             (mcg/kg/min) x 100 + phenylephrine: (mcg/kg/min) x 100 + vasopressin: (units/kg/hr) x
             100 + milrinone: (mcg/kg/min) x 15 + dopamine: (mcg/kg/min) x 1 + dobutamine:
             (mcg/kg/min) x 1 + calcium chloride: (mg/kg/hr) x 1]

        Exclusion Criteria:

          -  Age &gt; 1 month

          -  Documented sepsis

          -  Preoperative use of steroids &gt; 1 wk
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>N/A</minimum_age>
    <maximum_age>1 Month</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Heather A Dickerson, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Baylor College of Medicine</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Texas Children's Hospital</name>
      <address>
        <city>Houston</city>
        <state>Texas</state>
        <zip>77030</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <reference>
    <citation>Suominen PK, Dickerson HA, Moffett BS, Ranta SO, Mott AR, Price JF, Heinle JS, McKenzie ED, Fraser CD Jr, Chang AC. Hemodynamic effects of rescue protocol hydrocortisone in neonates with low cardiac output syndrome after cardiac surgery. Pediatr Crit Care Med. 2005 Nov;6(6):655-9.</citation>
    <PMID>16276331</PMID>
  </reference>
  <verification_date>April 2016</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>December 28, 2007</study_first_submitted>
  <study_first_submitted_qc>December 28, 2007</study_first_submitted_qc>
  <study_first_posted type="Estimate">January 10, 2008</study_first_posted>
  <results_first_submitted>February 23, 2016</results_first_submitted>
  <results_first_submitted_qc>April 20, 2016</results_first_submitted_qc>
  <results_first_posted type="Estimate">May 26, 2016</results_first_posted>
  <last_update_submitted>April 20, 2016</last_update_submitted>
  <last_update_submitted_qc>April 20, 2016</last_update_submitted_qc>
  <last_update_posted type="Estimate">May 26, 2016</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Baylor College of Medicine</investigator_affiliation>
    <investigator_full_name>Heather Dickerson</investigator_full_name>
    <investigator_title>MD</investigator_title>
  </responsible_party>
  <keyword>Congenital heart disease.</keyword>
  <keyword>Low cardiac output syndrome.</keyword>
  <keyword>Corticosteroids.</keyword>
  <keyword>Hydrocortisone.</keyword>
  <keyword>Blood pressure.</keyword>
  <keyword>Inotropes.</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Heart Diseases</mesh_term>
    <mesh_term>Critical Illness</mesh_term>
    <mesh_term>Heart Defects, Congenital</mesh_term>
    <mesh_term>Cardiac Output, Low</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Hydrocortisone 17-butyrate 21-propionate</mesh_term>
    <mesh_term>Hydrocortisone acetate</mesh_term>
    <mesh_term>Cortisol succinate</mesh_term>
    <mesh_term>Hydrocortisone</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>Hydrocortisone</title>
          <description>Subjects in this arm will receive a 5 day tapering course of hydrocortisone. Hydrocortisone: Hydrocortisone taper (100mg/m2/day --&gt; 25mg/m2/day) over 5 days intravenously.</description>
        </group>
        <group group_id="P2">
          <title>Placebo</title>
          <description>Subjects in this arm will receive 5 days of placebo. Placebo: Placebo for 5 days intravenously.</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="9"/>
                <participants group_id="P2" count="9"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="9"/>
                <participants group_id="P2" count="9"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Hydrocortisone</title>
          <description>Subjects in this arm will receive a 5 day tapering course of hydrocortisone. Hydrocortisone: Hydrocortisone taper (100mg/m2/day --&gt; 25mg/m2/day) over 5 days intravenously.</description>
        </group>
        <group group_id="B2">
          <title>Placebo</title>
          <description>Subjects in this arm will receive 5 days of placebo. Placebo: Placebo for 5 days intravenously.</description>
        </group>
        <group group_id="B3">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="9"/>
            <count group_id="B2" value="9"/>
            <count group_id="B3" value="18"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>&lt;=18 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="9"/>
                    <measurement group_id="B2" value="9"/>
                    <measurement group_id="B3" value="18"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Between 18 and 65 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>&gt;=65 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Age</title>
          <units>days</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="10" spread="10.58"/>
                    <measurement group_id="B2" value="7" spread="4.12"/>
                    <measurement group_id="B3" value="8.5" spread="7.94"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Gender</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Female</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="5"/>
                    <measurement group_id="B2" value="4"/>
                    <measurement group_id="B3" value="9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Male</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="4"/>
                    <measurement group_id="B2" value="5"/>
                    <measurement group_id="B3" value="9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>United States</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="9"/>
                    <measurement group_id="B2" value="9"/>
                    <measurement group_id="B3" value="18"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Inotrope score</title>
          <description>Inotrope score: epinephrine (mcg/kg/min x 100) + norepinephrine (mcg/kg/min x 100) + phenylephrine (mcg/kg/min x 100) + dopamine (mcg/kg/min x1) + dobutamine (mcg/kg/min x 1) + milrinone (mcg/kg/min x15). The higher the score the higher the inotrope requirements and generally the sicker the patient. Minimum would be 0. Maximum would be 85.</description>
          <units>units on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="23.46" spread="3.79"/>
                    <measurement group_id="B2" value="22.11" spread="2.31"/>
                    <measurement group_id="B3" value="22.78" spread="3.12"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Blood Pressure.</title>
        <description>Change in mean blood pressure recorded prior to (15 minutes prior to study drug) and subsequent to medication/placebo administration (at 2 days post drug administration).</description>
        <time_frame>2 days</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Hydrocortisone</title>
            <description>Subjects in this arm will receive a 5 day tapering course of hydrocortisone. Hydrocortisone: Hydrocortisone taper (100mg/m2/day --&gt; 25mg/m2/day) over 5 days intravenously.</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Subjects in this arm will receive 5 days of placebo. Placebo: Placebo for 5 days intravenously.</description>
          </group>
        </group_list>
        <measure>
          <title>Blood Pressure.</title>
          <description>Change in mean blood pressure recorded prior to (15 minutes prior to study drug) and subsequent to medication/placebo administration (at 2 days post drug administration).</description>
          <units>mmHg</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="9"/>
                <count group_id="O2" value="9"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="6" spread="7.86"/>
                    <measurement group_id="O2" value="5.89" spread="9.24"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change in Inotrope Score. This is the Change in the Inotrope Score Between 15 Minutes Prior to Drug Administration and at 2 Days After Drug Administration.</title>
        <description>Inotrope score: epinephrine (mcg/kg/min x 100) + norepinephrine (mcg/kg/min x 100) + phenylephrine (mcg/kg/min x 100) + dopamine (mcg/kg/min x1) + dobutamine (mcg/kg/min x 1) + milrinone (mcg/kg/min x15). A lower inotrope score is better with the minimum being 0 and the maximum being 85.</description>
        <time_frame>2 days</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Hydrocortisone</title>
            <description>Subjects in this arm will receive a 5 day tapering course of hydrocortisone. Hydrocortisone: Hydrocortisone taper (100mg/m2/day --&gt; 25mg/m2/day) over 5 days intravenously.</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Subjects in this arm will receive 5 days of placebo. Placebo: Placebo for 5 days intravenously.</description>
          </group>
        </group_list>
        <measure>
          <title>Change in Inotrope Score. This is the Change in the Inotrope Score Between 15 Minutes Prior to Drug Administration and at 2 Days After Drug Administration.</title>
          <description>Inotrope score: epinephrine (mcg/kg/min x 100) + norepinephrine (mcg/kg/min x 100) + phenylephrine (mcg/kg/min x 100) + dopamine (mcg/kg/min x1) + dobutamine (mcg/kg/min x 1) + milrinone (mcg/kg/min x15). A lower inotrope score is better with the minimum being 0 and the maximum being 85.</description>
          <units>units on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="9"/>
                <count group_id="O2" value="9"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="8.83" spread="9.61"/>
                    <measurement group_id="O2" value="7.17" spread="4.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>Duration of the the admission time in the intensive care unit and hospital stay (duration of the study). This time period averaged 45 days.</time_frame>
      <group_list>
        <group group_id="E1">
          <title>Hydrocortisone</title>
          <description>Subjects in this arm will receive a 5 day tapering course of hydrocortisone. Hydrocortisone: Hydrocortisone taper (100mg/m2/day --&gt; 25mg/m2/day) over 5 days intravenously.</description>
        </group>
        <group group_id="E2">
          <title>Placebo</title>
          <description>Subjects in this arm will receive 5 days of placebo. Placebo: Placebo for 5 days intravenously.</description>
        </group>
      </group_list>
      <serious_events>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="9"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Cardiac disorders</title>
            <event_list>
              <event>
                <sub_title>Death</sub_title>
                <description>Death likely underlying heart disease - worsening function &amp; arrhythmias. Study drug 9/20/04-9/24/04. No infections or bleeding. Weaned from inotropes after study drug. Deteriorated subsequently. Cleared by data safety monitoring board.</description>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="9"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0</frequency_threshold>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="9"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>All Principal Investigators ARE employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Dr. Heather Dickerson</name_or_title>
      <organization>Baylor College of Medicine</organization>
      <phone>832-826-5637</phone>
      <email>had@bcm.edu</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

